Deucravacitinib: A Novel TYK2 Inhibitor for the Treatment of Moderate-to-Severe Psoriasis
Kingston P, Blauvelt A, Strober B, Armstrong A. Deucravacitinib: A Novel TYK2 Inhibitor for the Treatment of Moderate-to-Severe Psoriasis. Journal Of Psoriasis And Psoriatic Arthritis 2023, 8: 156-165. PMID: 38188537, PMCID: PMC10768812, DOI: 10.1177/24755303231201336.Peer-Reviewed Original ResearchSevere plaque psoriasisTreatment of psoriasisPlaque psoriasisMechanism of actionLong-term extension studyNovel oral medicationsOral PDE4 inhibitorPalms/solesAcceptable safety profileHigh-risk patientsTreatment of adultsWeeks of treatmentTreatment of ModeratePivotal clinical studiesType I interferonPASI 75Tuberculosis evaluationSevere psoriasisIL-23Oral medicationsIL-12Blood testsSafety profilePsoriasis pathogenesisTriglyceride levelsTopical Management of Plaque Psoriasis-A Review and Case Series Discussion with Focus on Aryl Hydrocarbon Receptor Modulation.
Bruno M, Strober B, Del Rosso J. Topical Management of Plaque Psoriasis-A Review and Case Series Discussion with Focus on Aryl Hydrocarbon Receptor Modulation. The Journal Of Clinical And Aesthetic Dermatology 2023, 16: s3-s12. PMID: 38496799, PMCID: PMC10939505.Peer-Reviewed Original ResearchTopical treatmentTopical treatment of plaque psoriasisTreatment of plaque psoriasisAryl hydrocarbon receptor modulatorsTopical corticosteroid therapyUnited States Food and Drug AdministrationStates Food and Drug AdministrationTreatment of psoriasisFood and Drug AdministrationEffective mechanism of actionCorticosteroid therapyPlaque psoriasisTopical therapyTreatment armamentariumModulator therapyMechanism of actionNonsteroidal agentsReceptor modulatorsAryl hydrocarbon receptorFDA approvalDrug AdministrationModulating agentsPsoriasisTherapyDermatology community